In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mike Ward

London, UK
Mike has been writing, analysing and commenting on the life sciences industry for more than 30 years as a journalist and investment bank analyst. He has focused on business models, R&D strategies and how to finance innovation, and is often called upon by the industry's key stakeholders to provide thought leadership. In 2010 he was named European Mediscience Commentator of the Year and has appeared on the shortlist for that award on numerous occasions. When not commentating on all things pharma, Mike is engaged actively in pub quizzes, either as a competitor or a compiler. He is also a qualified FA soccer coach.
Set Alert for Articles By Mike Ward

Latest From Mike Ward

Waking Up Market To US Obstructive Sleep Apnea Epidemic

RespireRx president & CEO James Manuso explained to Scrip during the 2018 Biotech Showcase how the company is repurposing an existing drug to tackle the problem of sleep apnea.

Clinical Trials Companies

How NGM Bio Intends To Build An Old-School Biotech

NGM Biopharmaceuticals CEO Jeff Jonker discusses the company's lead program in NASH and its other R&D activities and business strategy in an interview with Scrip's Mike Ward.
Liver & Hepatic Research and Development Strategies

Probiodrug CEO Outlines Phase IIb Plans For Potential Alzheimer’s Treatments

Probiodrug is ramping up plans to run Phase IIb Alzheimer's disease trials on the back of biomarker data that indicates that its approach to targeting pyroglutamate-Abeta is a promising therapeutic strategy. CEO Konrad Glund spoke to Scrip at the 2018 Biotech Showcase.

Business Strategies Companies

GeNeuro Homes In On Ancestral Viral Genes To Treat Autoimmune Diseases

Focusing on an idea that many autoimmune diseases are caused by proteins from viral genes that are now embedded in human DNA, Swiss biotech GeNeuro is using the idea to develop therapeutics.
StartUps and SMEs Research and Development Strategies

Orchard Therapeutics Banks On Lentiviral Gene Therapy Potential

Armed with $110m raised in a Series B financing at the end of 2017, UK biotech Orchard Therapeutics is accelerating its efforts to lentiviral gene therapeutics into patients. 

Research & Development Immune Disorders
See All